Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.
about
Neuromyelitis optica pathogenesis and aquaporin 4B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized InflammationTherapy of NMO spectrum disordersUpdate on biomarkers in neuromyelitis opticaClinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directionsChallenges and opportunities in designing clinical trials for neuromyelitis opticaImmunology of neuromyelitis optica: a T cell-B cell collaborationMolecular pathogenesis of neuromyelitis opticaGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Neurologic indications for therapeutic plasma exchange: an update.Neurologic indications for therapeutic plasma exchange: 2011 update.Neurologic indications for therapeutic plasma exchange: 2013 update.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Devic's neuromyelitis optica: a critical review.Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosisNeuromyelitis optica - an update: 2007-2009Update on neuromyelitis optica: natural history and management.Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaTherapeutic plasma exchange in neuromyelitis optica: a case series.The treatment of neuromyelitis optica.Treatment of neuromyelitis optica: current debate.Management of optic neuritisUpdate on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Beneficial plasma exchange response in central nervous system inflammatory demyelination.Brain-reactive antibodies and disease.New insights into neuromyelitis opticaNeuromyelitis optica: an antibody-mediated disorder of the central nervous system.Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder.Current options for the treatment of optic neuritis.Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersClinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels.Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis.Neuromyelitis optica mimicking intramedullary tumor.Complement in multiple sclerosis: its role in disease and potential as a biomarker.Treatment of Neuromyelitis Optica: Review and Recommendations.Plasmapheresis for neurological disorders.
P2860
Q21245240-53AE9117-93C0-4ACC-B230-5835AF3C8F98Q26770852-54B37C18-B8A1-45EA-A694-7E316D1D2F0BQ26779910-7DB30AF8-CE7B-4CAC-9502-35DA4089AB92Q26799789-CAED9183-CDEC-48FA-AA92-D313B92D6E0EQ26824216-88645438-D1A2-45F7-A98E-9412B2D94AA7Q26999708-14432FE3-5B85-414D-AE0F-B28F436EDA0CQ27016045-473715E3-8F80-46BA-B87C-6726688E4364Q27021535-6A2846A6-C772-4AD9-B7A9-6289BBA150B7Q30276550-87E809BA-72A2-4189-90A2-A6CAD3B17ED0Q30454297-7693F67F-7211-4080-B985-FBFF77AA6E03Q30455391-04190969-D8EB-4B9A-A021-8F2799355CA9Q30458271-2406ED9D-A6C8-4C3B-9BAF-0DEC8C3C7D87Q30676331-EE63C059-AAD0-46F8-BFA3-F4E30C58E0DCQ30785267-9E737114-9DCE-4F7A-93C5-6C80142A831DQ31151651-90A07EC2-E2DF-4C81-BA78-79FAF0840708Q33611158-BA222CBB-B38B-47D6-9349-14FCCB4B3916Q33670918-C71BCCB8-465F-4B52-8997-19ECD9CC14ECQ33702126-D423B980-6D83-462B-BF3A-F0A01D6A24C6Q34072287-1B996BB9-D684-4A27-80B3-E3F5F0CD82A4Q34122035-472F4135-1C37-49E3-9940-29574672B677Q34338762-5CFF4929-81F6-429B-9FB5-D2A5BEA744F3Q34378423-49CB629F-D8F6-42E6-8054-562D107D945EQ34399291-89BBD320-DEE2-4880-A203-3D9C17E3D0D0Q34409070-36143D93-5504-4FA1-A189-4776E44846C7Q35049583-64FB25F3-7742-482B-9499-C60EBDC424E0Q35052199-949729C7-A91F-480A-9A39-F9E74A5EF371Q35100020-8397B116-34BF-4F13-9BBE-890D91D28831Q35458567-FF70F2B4-23DE-4680-BE98-3AC2C7A1F2A3Q35539641-B6E88E16-4C1E-48D9-9062-B3249EB62606Q35738898-9FBFEF47-CEE4-42FD-BB11-754D9C1F35BBQ36118869-297EB7C7-F738-403D-889E-E8838F8A6953Q36173222-4EF4532D-13C1-464F-995B-95A28197FF33Q36484394-439A456E-D2CD-447B-896E-E334E73A3E9CQ36528736-1807B95D-A109-4E55-8926-5E3ED7698631Q36696590-F527F9F5-E381-4F97-8261-2FF79098FC65Q36937059-38B4B5A4-1AD8-4C45-B668-2CD6133D5630Q37061002-E6DF0FFF-5BBB-453F-B45F-3D0964A990E0Q37336914-9498D663-A49C-43D2-AA0A-5A41F79E617AQ37588037-2CFB87D2-12BC-4437-A98C-E2DFD1C5EB94Q37600865-D084490F-B7B6-49D1-9FCF-236704B73B0B
P2860
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@en
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@nl
type
label
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@en
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@nl
prefLabel
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@en
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@nl
P2093
P2860
P356
P1476
Therapeutic efficacy of plasma ...... nts with neuromyelitis optica.
@en
P2093
P2860
P304
P356
10.1177/1352458506071174
P577
2007-01-01T00:00:00Z